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Abstract
Purpose To evaluate the impact on survival of the rela-
tive dose intensity (RDI) achieved in patients with early
breast cancer receiving anthracycline plus taxane-based
chemotherapy in the adjuvant setting.
Patients and methods Patients with early breast cancer
diagnosed from January 1999 through December 2006
were included. Dose intensity was evaluated according to
the number of delayed cycles and days and the percentage
of RDI.
Results A total of 231 breast cancer patients were inclu-
ded. Granulocyte colony-stimulating factor (G-CSF) was
given to 39 % of patients. Few patients delayed chemo-
therapy administration C2 cycles (6 %) and C15 days
(2 %), and the majority of them received C85 % of the
RDI (98 %). Overall survival was statistically lower at
5 years in patients who received \85 % of RDI in com-
parison with those who received C85 % of RDI (80 vs.
97 %; p = 0.026).
Conclusions With a wide use of G-CSF in patients treated
with adjuvant anthracyclines plus taxane-based schedules,
98 % of patients received a RDI C85 %. A significant
although inconsistent impairment of survival was found in
those patients with lower RDI.
Keywords Anthracyclines  Early breast cancer 
Granulocyte colony-stimulating factor  Observational
study  Taxanes
Introduction
Adjuvant chemotherapy has shown increased survival in
early breast cancer. About 6 months of adjuvant anthra-
cycline-based polychemotherapy schedules (FAC or FEC)
reduced the annual breast cancer death rate by about 38 %
for women younger than 50 years and by about 20 % for
those diagnosed at 50–69 years of age [1] compared to
non-anthracycline-containing schedules.
The benefit of addition of taxanes to anthracycline-based
schedules was confirmed in a meta-analysis of thirteen
studies including 22,903 patients [2]. The pooled hazard ratio
(HR) estimated was 0.83 for disease-free survival (DFS) and
0.85 for overall survival (OS). The risk reduction was not
influenced by the type of taxane, by estrogen receptor (ER)
expression, by the number of axillary metastases (N1 to 3 vs.
N4), or by the patient’s age/menopausal status.
Several trials have studied the relationship between dose
intensity and survival. Muss et al. [3] observed in a retro-
spective study with 6,487 older and younger patients with
lymph node-positive breast cancer that the dose level and
the dose intensity of chemotherapy were significantly
related to OS and DFS, independently of the patient’s age.
The observed reduction in the hazard of failure of relapse
was 22 % for patients who received more intensive che-
motherapy in comparison with those who received less
intensive chemotherapy (HR: 0.78; 95 % confidence
interval (CI), 0.72–0.85).
In another recent retrospective study reported by our
group, the dose response effect was identified as a crucial
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factor in the administration of anthracycline-based non-
taxane schedules for the adjuvant treatment of early breast
cancer [4]. Optimal delivery of the programmed chemo-
therapy improved OS and DFS. Thus, delays and/or
reductions of chemotherapy should be avoided whenever
possible to achieve the maximal benefit for the patient.
Breast cancer treatment is not exempt from adverse
events, with neutropenia and febrile neutropenia being
two of the most common and life-threatening side
effects of adjuvant chemotherapy. Although the inci-
dence of these adverse events may be minimized with
dose reductions and delays in treatment, the most
common strategy to maintain dose intensity is to
administer granulocyte colony-stimulating factors (G-
CSF) during chemotherapy administration [5]. Accord-
ing to the recommendations of the American Society of
Clinical Oncology, the use of G-CSF as primary pro-
phylaxis is justified in patients who are at high risk of
febrile neutropenia based on age, medical history, dis-
ease characteristics, and the myelotoxicity risk of the
chemotherapy regimen given. Moreover, it is recognized
that G-CSF may allow a modest to moderate increase in
the dose intensity of chemotherapy [6].
Studies with dose-dense taxane-containing regimens
followed with G-CSF support have shown contradictory
results on survival in early breast cancer in different studies
[7, 8]. However, little is known about the impact of
maintaining relative dose intensity (RDI) in conventional
chemotherapy schedules including taxanes.
The aim of our study was to assess the impact on DFS
and OS of dose-density of anthracyclines plus taxane-based
schedules in the adjuvant setting of patients with early
breast cancer. A secondary objective of this study was to
evaluate the dose intensity achieved in a non-selected
population treated with adjuvant anthracyclines and tax-




A retrospective database analysis was performed in
January 2010. The database was created in 1980 and,
since then, clinical data from all patients with breast
cancer treated at the Hospital Clı´nico Universitario of
Valencia (Spain) have been entered from diagnosis to
death.
Confidentiality of patients’ data was maintained
throughout the study. Data retrieval was performed by two
data managers. Four independent medical oncologists
verified 15 % of the retrieved data against the original
medical records to confirm accuracy. The study was per-
formed according to local legislation and the study protocol
was approved by the Ethics Committee of Hospital Clı´nico
Universitario of Valencia (Spain).
Study procedures
Patients to be included into this retrospective analysis were
to have a diagnosis of early breast cancer from January
1999 through December 2006, a surgical procedure as the
primary treatment of the disease, and an anthracycline plus
taxane-based chemotherapy given in the adjuvant setting.
In the adjuvant setting, patients received anthracyclines
plus either docetaxel or paclitaxel in different schedules
based on the individual characteristics of the patient and
the tumor. Hormonal therapy was started after chemo-
therapy completion and continued for 5 years in all patients
with hormone receptor-positive tumors. Radiotherapy was
initiated within approximately 4 weeks after the last cycle
of chemotherapy in all patients who had undergone breast-
conserving surgery or who had a tumor size [5 cm or C4
lymph nodes affected. G-CSF support was administered as
primary or secondary prophylaxis, or to manage adverse
events at clinician’s discretion.
Data retrieved included patient age, year of diagnosis,
tumor stage, histological grade, as well as menopausal and
hormonal receptor status. Other treatment-related data were
retrieved such as type of surgery and radiotherapy, the type
of hormonal therapy given, chemotherapy schedules
administered, mean percentage of administered dose
throughout the cycles, the number of chemotherapy cycles
delayed and the number of delayed days during chemo-
therapy treatment. Lastly, the final day of follow-up along
with any event (disease recurrence or death) that occurred
during the follow-up period was also noted. To ensure
consistency of data, patients not diagnosed in this hospital
were excluded.
Statistical analysis
The primary objective of this analysis was to evaluate
whether the optimal delivery of an anthracycline plus
taxane-based schedule in the adjuvant setting of patients
with early breast cancer could impact on DFS and OS at
5 years. OS at 5 years was defined as being alive 5 years
after cancer diagnosis. Similarly, DFS at 5 years was
defined as being alive, with no disease recurrence, 5 years
after cancer diagnosis. Secondary objectives included
evaluating the dose intensity achieved in a non-selected
population treated with anthracyclines and taxanes in
whom G-CSF was administered at clinician’s discretion
and knowing clinical, epidemiological and treatment
characteristics of this population.
Clin Transl Oncol (2014) 16:814–822 815
123
Three variables were chosen to assess chemotherapy
delivery to the patient, which were the number of delayed
cycles, the number of delayed days, and the percentage of
RDI given. The number of delayed cycles was based on
whether the patient had more than two cycles with
C3 days of delay with respect to the planned schedule
(\2 delayed cycles, C2 delayed cycles). The number of
delayed days during treatment administration was based
on whether or not the patient’s chemotherapy had to be
delayed more than 14 days overall (\15 delayed days,
C15 delayed days). Finally, the RDI was based on
whether or not the patient’s RDI was less than 85 %
(C85 %, \85 %). RDI was calculated as the mean per-
centage of administered dose throughout the entire
treatment multiplied by the ratio of the number of
treatment days as planned to the number of treatment
days as planned plus the number of delayed days. DFS
and OS at different time points were defined as the time
from cancer diagnosis until the occurrence of the event
(disease recurrence or death).
Collected variables in the case report form were pre-
sented with absolute and relative frequencies for qualitative
variables, and with measures of association and dispersion
for quantitative variables (mean, standard deviation, med-
ian, minimum and maximum). Times to event variables
were described using the Kaplan–Meier method. Possible
relationships between qualitative variables were studied by
Cox regression. All statistical tests were performed against
a two-sided, alternative hypothesis using a significance
level of 0.05 and a 95 % CI. The SPSS (version 17.0)
statistical program (SPSS Inc., Chicago, IL, USA) was
used for the statistical analysis.
Table 1 Patient characteristics at diagnosis (n = 231)
Characteristics n %
Age (years), n = 231
Median (range) 59 (26–80)
Treatment period, n = 231
1999–2002 100 43
2002–2007 131 57















ER?, n = 229 176 77
PR?, n = 226 147 65
ER? or PR?, n = 226 187 83
HER2?, n = 194 96 49
Triple negative (ER-, PR-, HER2-), n = 192 14 7
Menopausal status, n = 230
Pre-/perimenopausal 101 44
Postmenopausal 129 56
Hormonal treatment and related agents, n = 231
Yes 188 81
ER estrogen receptor, PR progesterone receptor, HER2 human epi-
dermal growth factor receptor 2
Table 2 Characteristics of the treatments administered to the patients
Adjuvant chemotherapy (cycles), n = 231 n %
With docetaxel 157 68
TAC 9 6 46 20
ET 9 4 ? X 9 4 39 17
EC 9 4 ? T 9 4 39 17
AT 9 4 ? CMF 9 4 21 9
A 9 3 ? T 9 3 ? CMF 9 3 12 5
With paclitaxel 74 32
FAC 9 4 ? T 9 8 48 21
AT 9 4 ? CMF 9 3 13 5
FEC 9 4 ? T 9 8 11 5
AC 9 4 ? T 9 8 or T 9 12 2 1
Chemotherapy administration, n = 231 n %
Delayed cycles
\2 cycles 216 94
C2 cycles 15 6
Delayed days
\15 days 226 98
C15 days 5 2
Relative dose intensity
C85 % 226 98
\85 % 5 2
Prophylaxis with G-CSF, n = 231 n %
Yes 84 36
Primary prophylaxis 55 24
Secondary prophylaxis 29 12
No 147 64
G-CSF given later to treat neutropenia 8 3
A doxorubicin, C cyclophosphamide, E epirubicin, F 5-fluorouracil,
G-CSF granulocyte colony-stimulating factor, M methotrexate,
T taxane (docetaxel or paclitaxel), X capecitabine
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Results
Patient’s characteristics at diagnosis
A total of 231 patients with early breast cancer diagnosed
from 1999 to 2007 in our institution were included in this
analysis. Patients’ characteristics at diagnosis are shown in
Table 1.
Treatment administration in the adjuvant setting
All patients underwent surgery, either conservative (62 %)
or mastectomy (38 %). Radiotherapy was given to 70 % of
patients, and 81 % of them received hormonal therapies
such as tamoxifen (72 % of patients), anastrozole (31 %),
exemestane (15 %) and letrozole (15 %). All patients
received adjuvant chemotherapy with anthracyclines and
taxanes, of whom 68 % included docetaxel and 32 %
included paclitaxel. The chemotherapy schedule most fre-
quently administered was FAC 9 4 ? T 9 8 (21 %) fol-
lowed by TAC 9 6 (20 %). Other treatment schedules
given are described in Table 2.
At clinician’s discretion, G-CSF was given as primary or
secondary prophylaxis to 24 and 12 % of patients,
respectively. Additionally, 3 % of patients received G-CSF
later on to manage toxicity. G-CSF was mostly given to
patients treated with docetaxel-based schedules, either as
primary (98 %) or secondary prophylaxis (86 %). Only five
patients treated with paclitaxel and anthracyclines received
G-CSF, four as secondary prophylaxis (Table 3). Clini-
cians mostly decided to give G-CSF as primary prophylaxis
in patients receiving TAC schedule (78 %), followed by
those treated ET ? X (46 %). However, in patients treated
with EC ? T, G-CSF was not given as primary prophy-
laxis but had to be introduced as secondary prophylaxis in
44 % of patients. None of the patients treated with
AT ? CMF or A ? T ? CMF received any type of
prophylaxis with G-CSF. Among patients receiving pac-
litaxel-based schedules, only one patient treated with
FAC ? T received primary prophylaxis with G-CSF, and
in four additional patients G-CSF was introduced later on.
Overall, few patients had to delay and/or reduce dosages
during the administration of adjuvant chemotherapy. Five
patients (2 %) received less than 85 % of RDI, 15 patients
(6 %) delayed two or more treatment cycles, and five
patients (2 %) had a delay of 15 days or more. Severe
neutropenia and febrile neutropenia were present in 42
(18 %) and 23 patients (10 %), respectively.
Impact of adjuvant chemotherapy on DFS and OS
The probability of surviving without recurrence of the
disease at 5 and 10 years was 88 % (95 % CI 84–92) and
80 % (95 % CI 72–87), respectively; and the probability of
being alive, with or without disease recurrence, was 97 %
(95 % CI 95–99) and 82 % (95 % CI 72–92), respectively
(Tables 4, 5).
As shown in Tables 4 and 5 and Figs. 1 and 2, DFS and
OS were not affected by the number of delayed cycles and
the number of delayed days. However, patients who
received a reduced RDI (\85 %) had significantly lower
probability of survival without recurrence of disease at
2 years in comparison with patients who received C85 %
(80 vs. 99 %; p = 0.001), and a lower probability of being
alive at 4 and 5 years (98 vs. 80 %; p = 0.014; 97 vs.
80 %; p = 0.026, respectively).
Table 3 Administration of prophylaxis with G-CSF according to investigator’s criteria
Treatment Prophylaxis with G-CSF
No prophylaxis, n (%) Primary, n (%) Secondary, n (%)
With docetaxel
TAC 9 6, n = 46 7 (15) 36 (78) 3 (7)
ET 9 4 ? X 9 4, n = 39 16 (41) 18 (46) 5 (13)
EC 9 4 ? T 9 4, n = 39 22 (56) 0 (0) 17 (44)
AT 9 4 ? CMF 9 4, n = 21 21 (100) 0 (0) 0 (0)
A 9 3 ? T 9 3 ? CMF 9 3, n = 12 12 (100) 0 (0) 0 (0)
With paclitaxel
FAC 9 4 ? T 9 8, n = 48 43 (90) 1 (2) 4 (8)
AT 9 4 ? CMF 9 3, n = 13 13 (100) 0 (0) 0 (0)
FEC 9 4 ? T 9 8, n = 11 11 (100) 0 (0) 0 (0)
AC 9 4 ? T 9 8 or T 9 12, n = 2 2 (100) 0 (0) 0 (0)
Total 147 (64) 55 (24) 29 (12)
A doxorubicin, C cyclophosphamide, CI confidence interval, E epirubicin, F 5-fluorouracil, G-CSF granulocyte colony-stimulating factor,
M methotrexate, T taxane (docetaxel or paclitaxel), X capecitabine
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Discussion
Our results showed that DFS and OS were not affected by
delays in scheduled chemotherapy. Only those patients
who received a reduced RDI had a lower probability of
survival without recurrence of disease at 2 years. Also,
patients who received reduced RDI had a lower probability
of being alive at 4 and 5 years. However, the impact on
DFS and OS is not consistent along years.
Low RDI is a common issue in clinical practice. In a
population study of 1,243 community oncology practice in
the USA with data from 20,799 early breast cancer patients
showed that 36.5 % presented dose reductions of C15 days
and 24.9 % had treatment delays C7 days resulting in
55.5 % of patients receiving RDI\85 %. Multivariate ana-
lysis identified the absence of primary prophylaxis with
G-CSF as one of the independent predictors for low RDI [9].
A later study by the same group including 2,280 women with
early breast cancer from community practice, low dose
intensity in conventional schedules was reduced, probably
due to the introduction of G-CSF, but the frequency of
inappropriate chemotherapy delivery was 31, 24 and 26 %
for dose delays, dose reductions and low RDI, respectively
[10]. Strikingly, in our series the proportion of patients with
Table 4 Impact of chemotherapy delivery on disease-free survival















2 years 99 93 98 100 99 80 98 (97–100)
p 0.126 0.765 0.001*
4 years 91 93 91 100 91 80 91 (87–95)
p 0.791 0.491 0.315
5 years 88 93 88 100 88 80 88 (84–92)
p 0.562 0.418 0.500
6 years 86 93 86 100 87 80 87 (82–91)
p 0.473 0.375 0.563
8 years 84 93 85 100 85 80 84 (79–90)
p 0.465 0.366 0.621
10 years 79 93 79 100 80 80 80 (72–87)
p 0.418 0.323 0.695
CI confidence interval, DFS disease-free survival, RDI relative dose intensity
* Statistically significant
Table 5 Impact of chemotherapy delivery on overall survival















2 years 99 93 99 100 99 100 99 (97–100)
p 0.061 0.796 0.796
4 years 98 93 97 100 98 80 97 (95–99)
p 0.302 0.712 0.014*
5 years 97 93 97 100 97 80 97 (95–99)
p 0.395 0.687 0.026*
6 years 93 93 93 100 93 80 93 (89–97)
p 0.849 0.539 0.135
8 years 92 93 92 100 92 80 92 (87–96)
p 0.902 0.514 0.165
10 years 81 93 81 100 82 80 82 (72–92)
p 0.888 0.418 0.245
CI confidence interval, RDI relative dose intensity, OS overall survival
* Statistically significant
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low RDI was very small (2 %). This is probably as a con-
sequence of a wide use of prophylactic G-CSF in our prac-
tice. This difference in sample size between patients with
normal versus low RDI is the main limitation of our study
and this issue precludes definitive conclusions.
In 2009, our group, Chirivella et al. [4] assessed how the
suboptimal delivery of an anthracycline-based non-taxane
adjuvant chemotherapy may impact the outcome of patients
with early breast cancer. Delays of[2 cycles, C15 delayed
days or RDI\85 % had a statistical impact on DFS. More-
over, when clinically relevant disease characteristics were
controlled, such as the number of lymph nodes affected and
the hormonal receptor status, the significance on DFS
remained. However, in contrast with our study, prophylactic
G-CSF was not widely used, as a result, the percentage of
patients who had delayed chemotherapy administration or
who received a reduced dose of chemotherapy was much
higher than in our series. Patients who delayed chemotherapy
[2 cycles or C15 days were 27 and 29 %, respectively, and
12 % received \85 % of RDI. In the current analysis, in
which 36 % of patients received G-CSF and primary or
secondary prophylaxis at clinician’s discretion, these
Fig. 1 a Number of delayed cycles (\2 cycles, C2 cycles), b number of delayed days (\15, C15 days), c RDI (C85, \85 %)
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percentages went down to 6, 2 and 2 %, respectively. Likely
as a result of this, the impact observed in the outcome of
patients in terms of DFS and OS was also smaller.
The role of G-CSF on maintaining an appropriate RDI in
taxanes-containing schedules for breast cancer patients has
been previously analyzed. Martin et al. [11] assessed the
toxicity and the health-related quality of life of patients
with breast cancer treated with anthracyclines, with or
without taxanes, and with or without primary prophylactic
G-CSF. In the group of patients treated with taxanes, 96 %
of patients who received prophylaxis with G-CSF com-
pleted the six-cycle schedule, in comparison with 90 % of
patients without G-CSF prophylaxis (p = 0.019). In com-
parison with patients who received secondary prophylaxis
with G-CSF, primary prophylaxis was associated with a
significant reduction in the number of cases of febrile
neutropenia (26 vs. 7 %; p \ 0.001) and grade 2/3 anemia
(47 vs. 28 %; p \ 0.001); and fewer patients required red
cell transfusions (7 vs. 2 %; p \ 0.010). Primary prophy-
laxis with G-CSF was also associated with a significant
Fig. 2 a Number of delayed cycles (\2 cycles, C2 cycles), b number of delayed days (\15, C15 days), c RDI (C85, \85 %)
820 Clin Transl Oncol (2014) 16:814–822
123
reduction in the incidence of asthenia, anorexia, myalgia,
nail disorders and stomatitis compared with secondary
prophylactic G-CSF. The reduction of these adverse events
would facilitate compliance of the treatment as we have
observed in our study.
It has been demonstrated that TAC schedules are more
toxic than FAC schedules, not only with respect to neutro-
penic fever events, but also with respect to many extrahe-
matological side-effects such as asthenia, stomatitis,
diarrhea and myalgia [12]. In our study, those patients who
received more aggressive treatment schedules, primary
prophylaxis with G-CSF has been widely used in highly toxic
regimens such as TAC. Overall, 78 % of patients treated with
TAC and 46 % of patients treated with ET ? X received
primary prophylaxis with G-CSF. However, when less toxic
schedules were given, only 2 % received primary prophy-
laxis and 8 % received secondary prophylaxis. Interestingly,
none of the patients treated with EC ? T received G-CSF as
primary prophylaxis, but in 44 % of them it had to be
introduced later on as secondary prophylaxis. Hence, it may
be more beneficial for certain patients treated with EC ? T
to be given G-CSF from the beginning to avoid the occur-
rence of adverse events later on.
According to clinical guidelines, use of G-CSF is rec-
ommended to maintain chemotherapy if reduction of dose-
density is associated to poor prognosis or if the risk of
febrile neutropenia is high (C20 %) [13]. The important
rate of prophylactic G-CSF administration in our study,
although in accordance to clinical guidelines, may be a
relevant factor to explain the high rate of RDI [85 %
observed in our study.
Strikingly, a Cochrane Database Systematic Review
including eight randomized clinical trials assessing the
effect of prophylactic G-CSF showed evidence of pre-
vention of febrile neutropenia but failed to confirm any
effect on maintaining dose density in breast cancer
patients [14]. However, in most of the trials analyzed the
chemotherapy regimens used had a risk of febrile neu-
tropenia that was below the threshold at which current
guidelines recommend routine primary prophylaxis.
Moreover the small number of evaluable patients in
some trials and the variability of definitions may strongly
bias these findings.
Of note, at 5 and 10 years, the rate of DFS in our study
was 88 and 80 %, respectively; and the rate of OS was 97
and 82 %, respectively. These data are outstanding taking
into account, that more than a half of our patients were
diagnosed with stage III breast cancer. Although it is
impossible to identify which factors were responsible for
these results, it seems reasonable to suppose that both the
addition of taxanes to an anthracycline-based chemother-
apy in the adjuvant setting, together with the optimal
administration of chemotherapy, may have played an
important role.
In fact, it cannot be discarded that reduced survival in
many treatment schedules in the adjuvant setting may be
due, at least in part, to a reduced compliance of the RDI
[15]. Also, the high frequencies of adverse events that
occur as a result of more aggressive therapies further
hinder compliance with therapy. In this respect, the
administration of prophylactic G-CSF at clinician’s dis-
cretion in those patients receiving more aggressive
schedules could help to improve this compliance. On the
other hand, it is important to note that nodes positivity
and hormone receptors are key variables related with
outcome in patients with breast cancer. However, in our
study the number of patients with RDI \85 % is too
small to conduct a multivariate analysis on this relevant
issue.
In summary, our results are inconclusive for the primary
endpoint. However, despite the previously mentioned
limitations, our results suggest that, with the adequate use
of G-CSF in patients with breast cancer treated with
anthracyclines plus taxane-based schedules in the adjuvant
setting, optimal chemotherapy administration could be
achieved in almost all patients.
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